Title(s): 
NRG-GY005. A Randomized Phase II/III study of the combination of Cediranib and Olaparib compared to Cediranib or Olaparib alone, or Standard of care chemotherapy in women with recurrent platinum-resistant or -refractory ovarian, fallopian tube, or primary peritoneal cancer (COCOS)
Investigator(s): Esther Rehmus, MD
Contact Information: McDowell Cancer Research at 330.344.6348